Search - tctmd.com

Displaying 401 - 420 of 570

Sort: Relevancy | Date

News Daily News

Aspirin Should Play Limited Role in Primary Prevention: Review

Michael O'Riordan

November 27, 2018

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Michael O'Riordan

November 06, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Michael O'Riordan

October 30, 2018

News Daily News

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Michael O'Riordan

October 25, 2018

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

News Conference News TCT 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Michael O'Riordan

October 05, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Daily News

Aspirin Falters Yet Again in Primary Prevention: ASPREE

Michael O'Riordan

September 17, 2018

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

Hospital Readmissions at 30 Days Declining for Stroke Patients

Michael O'Riordan

August 20, 2018

Advertisement

Aspirin Should Play Limited Role in Primary Prevention: Review

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Aspirin Falters Yet Again in Primary Prevention: ASPREE

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Hospital Readmissions at 30 Days Declining for Stroke Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content